Table 1.
Demographics of the BSRI and McMaster cohorts.
Table 2.
Pair-wise analysis of HLA Class I phenotype frequencies* in asymptomatic (AS), symptomatic (S), and neuroinvasive disease (ND) groups of WNV+ subjects.
Table 3.
Pair-wise analysis of HLA Class II phenotype frequencies* in asymptomatic (AS), symptomatic (S), and neuroinvasive disease (ND) groups of WNV+ subjects.
Figure 1.
Combinations of “susceptible” (S) and “protective” (P) alleles.
The histogram displays the percentage of subjects with the phenotype indicated below the X axis in the three WNV+ groups: asymptomatic (AS), symptomatic (S), and having a neuroinvasive disease (ND). ** P<0.01 and * P<0.05.
Table 4.
Combined effect of age and allele phenotype on disease outcome using logistic regression analysis comparing asymptomatic (AS), symptomatic (S), and neuroinvasive disease (ND) outcome groups.
Figure 2.
“Susceptible” and “protective” alleles in the North American population and in the WNV+ cohort.
The histogram displays the allele frequency of each “susceptible” and “protective” allele in the North American population and in the asymptomatic (AS), symptomatic (S), and having neuroinvasive disease (ND) WNV+ individuals. * P<0.05.
Figure 3.
“Susceptible” and “protective” allele frequencies in world populations.
The histogram displays the allele frequency of each “susceptible” and “protective” allele in various world populations. The North and sub-Saharan Africa were regrouped under Africa, North and South America were regrouped under New World, and Oceania, northwest, southeast, and southwest Asia were regrouped under Asia, Australia represents aboriginal populations only. *** P<0.0001 and * P<0.05 for Europe vs. comparison population.